Ассоциация «Национальная Ассоциация Фтизиатров» 191036, Санкт-Петербург, Лиговский пр., д. 2-4



страница11/11
Дата30.04.2016
Размер0.75 Mb.
1   2   3   4   5   6   7   8   9   10   11

Список литературы


  1. Проекты методических рекомендаций. Концепции химиотерапии и этиологической (микробиологической и молекулярно-биологической диагностики туберкулеза в Российской Федерации на современном этапе. Медицинский альянс 2012; 1; 5-38.

  2. Приказ Министерства здравоохранения Российской Федерации от 5 августа 2003 г. N 330 «О мерах по совершенствованию лечебного питания в лечебно-профилактических учреждениях Российской Федерации" .

  3. Приказ Министерства здравоохранения и социального развития Российской Федерации (Минздравсоцразвития России) от 26 апреля 2006 г. N 316 г. Москва. О внесении изменений в приказ Министерства здравоохранения Российской Федерации от 5 августа 2003 г. N 330 "О мерах по совершенствованию лечебного питания в лечебно-профилактических учреждениях Российской Федерации".

  4. Ерохин В.В., Ловачёва О.В., Лепёха Л.Н., Васильева И.А., Багдасарян Т.Р., Розенберг О.А. Комплексное лечение деструктивного туберкулёза лёгких с использованием препарата природного сурфактанта “сурфактант-БЛ”. Методические рекомендации. Москва, 2010. 22с.

  5. Ерохин В.В., Васильева И.А., Эргешов А.Э., Самойлова А.Г. Биочиповая технология повышает эффективность лечения МЛУ туберкулёза. Современные медицинские технологии. - 2010. -№5. С.82-83.

  6. Васильева И.А., Черноусова Л.Н., Эргешов А.Э. Эффективность режима химиотерапии по результатам биочипового метода определения МЛУ МБТ.

  7. Васильева И.А., Багдасарян Т.Р., Самойлова А.Г., Эргешов А.Э. Эффективность комплексного лечения больных туберкулезом легких с множественной и широкой лекарственной устойчивостью микобактерий.- Туберкулез и болезни легких, 2011. – № 4.- С.81.

  8. Васильева И.А., Самойлова А.Г., Зимина В.Н. и др. Опыт применения линезолида в комплексном лечении больных туберкулезом с широкой лекарственной устойчивостью возбудителя.- Туберкулез и болезни легких, 2010 – С. 17-20.

  9. Васильева И.А., Самойлова А.Г., Багдасарян Т.Р., Зимина В.Н., Черноусова Л.Н.. Зависимость результатов лечения больных туберкулезом легких от спектра лекарственной устойчивости возбудителя. - Туберкулез и болезни легких, 2011. - № 10. - С. 28.

  10. Васильева И.А., Эргешов А.Э., Самойлова А.Г., Киселева Ю.Ю.,. Иванов А.К, Яблонский П.К. Отдаленные результаты применения стандартных режимов химиотерапии у больных туберкулезом органов дыхания. - Туберкулез и болезни легких, 2012.-№4.- С. 3-8.

  11. Васильева И.А., Сигаев А.Т., Чуканов В.И. Искусственный пневмоперитонеум в комплексном лечении больных туберкулёзом лёгких, выделяющих лекарственно устойчивые микобактерии туберкулёза. Проблемы туберкулёза и болезней лёгких. -М.-2006. -№8. С.23-26.

  12. Багдасарян Т.Р., Чуканов В.И., Васильева И.А. Пневмоперитонеум в лечении больных лекарственно устойчивым туберкулёзом лёгких. Сборник трудов Республиканской научн-практ. конф. “Организация борьбы с туберкулёзом в Беларуси в условиях повышенного роста лекарствннной резистентности МБТ”, Беларусь. Брест, 2006. С.27

  13. Розенберг О.А., Ловачёва О.В., Васильева И.А., Багдасарян Т,.Р., Шергина Е.А. Ерохин В.В. Сурфактант-терапия при лечении деструктивного туберкулёза с лекарственной устойчивостью возбудителя. Туберкулёз и болезни лёгких. -М. -2011. -№5. С.136-137

  14. Ловачёва О.В., Шумская И.Ю., Туровцева Ю.В., Васильева И.А., Эргешов А.Э. Эндобронхиальный клапан в лечении деструктивного лекарственно устойчивого туберкулёза. Туберкулёз и болезни лёгких. -М. -2011. -№5. С.28-29

  15. Ловачёва О.В., Сивокозов И.В., Эргешов А.Э., Васильева И.А., Багдасарян Т.Р. Использование клапанного бронхоблокатора в лечении больных с детсруктивным туберкулёзом лёгких. Проблемы туберкулёза и болезней лёгких. -М. -2008. -№10. С.58-61

  16. А. В. Левин, Е. А. Цеймах, П. Е. Зимонин Применение клапанной бронхоблокации при осложнённом туберкулёзе лёгких. - Барнаул, 2008. - 29 с.

  17. Применение искусственного пневмоперитонеума и пневмоторакса в лечении деструктивного туберкулеза легких в современных условиях. Методические рекомендации МЗ РФ. – Проблемы туберкулеза, 2003. - №2.- с. 50-53

  18. Кильдюшева Е.И., Скорняков С.Н., Медвинский И.Д., Мотус И.Я., Залетаева Г.Е., Савельев А.В. Пневмоперитонеум в комплексном лечении распространенных форм деструктивного туберкулеза легких. Уральский медицинский журнал 2013, 2, 69-75.

  19. БаласанянцГ.С., Галкин В.Б. . Туберкулез с множественной и широкой лекарственной устойчивостью – актуальная эпидемиологическая проблема . - Профилактическая и клиническая медицина. – СПб., 2011. - № 3 - С.138 – 142

  20. Самойлова А.Г., Васильева И.А., Иванов А.К., Галкин В.Б., Марьяндышев А.О., Яблонский П.К.. Эффективность стандартных режимов химиотерапии в зависимости от лекарственной чувствительности возбудителя.// Туберкулез и болезни легких.- 2012, №8. - стр.23-29

  21. Торкатюк Е.А., Баласанянц Г.С. Современные проблемы широкой лекарственной устойчивости микобактерий туберкулеза. -Инфекция и иммунитет. Материалы X съезда Всероссийского научно-практического общества эпидемиологов, микробиологов и паразитологов. – 2012. - Том 2, № 1–2. – С.327.

  22. Belilovsky E, Galkin V, Danilova I. Long-term outcomes of treatment of new pulmonary tuberculosis patients in view of MDR-TB treatment effectiveness. - /43st Union World Conference on Lung Health,Malaysia, abstract book – 2012. ––V.16, N12.- S. 183. - PC-791-15

  23. Balasanyants G., Belilovsky E., Galkin V., Yablonsky P., Shulgina M. Formation of MDR/XDR-TB indicators in the North-West District of Russia - The International J. of Tuberculosis and Lung Disease. 44st Union World Conference on Lung Health, abstract book - Paris, 2013.- V.17, N12.- S. 492-493. (PC-915-03)

  24. Vasilyeva I, Samoilova A, Chernousova L, Larionova E. Analysis of patterns of multidrug-resistance in M. tuberculosis PS-852-28  The International Journal of Tuberculosis and Lung Disease, - volume 15, number 11, Nobember 2011, supplment 3. - S 159

  25. Vasilyeva I., Samoilova A., Bagdasaryan T., Ergeshov A. Linezolide in complex treatment of XDR-TB patients. European Respiratory Journal, 21-th ERS Annual Congress, Abstract book, Amsterdam, The Netherlands -2011. P.811s

  26. Falzon D., Jaramillo E., Schu¨nemann H.J., Arentz M., Bauer M., Bayona J., Blanc L.,. Caminero J.A, Daley C.L., Duncombe C., Fitzpatrick C., Gebhard A., Getahun H., Henkens M., Holtz T.H., Keravec J., Keshavjee S., Khan A.J., Kulier R., Leimane V., Lienhardt C., Lu C., Mariandyshev A.et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516–528.

  27. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update. Geneva, WHO, 2011. p.33

  28. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis, 2006, Geneva, WHO, 174р.

  29. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva, WHO, 2010 (WHO/HTM/TB/2010.3).

  30. Global tuberculosis control: WHO report 2010. Geneva, WHO, 2010 (WHO/HTM/TB/2010.7).

  31. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153–161.

  32. Resolution WHA62.15. Prevention and control of multidrug resistant tuberculosis and extensively drug-resistant tuberculosis. In: Sixty-second World Health Assembly: Resolutions and Decisions, Annexes. Geneva, WHO, 2009 (WHA62/2009/REC/ Available from: apps.who.int/gb/ebwha/pdf_files/WHA62-REC1/WHA62_REC1-en.pdf

  33. Guidelines for the programmatic management of drug-resistant tuberculosis. 1st Edn. Geneva, WHO, 2006 (WHO/HTM/TB/2006.361).

  34. Guidelines for the programmatic management of drug-resistant tuberculosis, Emergency update 2008. Geneva, WHO, 2008 (WHO/HTM/TB/2008.402).

  35. Shukhobodskaya E, Falzon D, Jaramillo E. Evaluation of the WHO guidelines on programmatic management of drug-resistant tuberculosis. Available from: www.worldlunghealth.org/Conf2009/website/assets/files/Abstract_Book_2009_Web.pdf

  36. Richardson WS, Wilson MC, Nishikawa J, et al. The well-built clinical question: a key to evidence-based decisions. ACP J Club 1995; 123: A12–A13.

  37. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, John Wiley & Sons, 2008.

  38. Global burden of disease 2004 update: disability weights for diseases and conditions. Geneva, WHO, 2004. Available from: www.who.int/healthinfo/global_burden_disease/GBD2004_DisabilityWeights.pdf

  39. GuyattGH, OxmanAD, Kunz R, et al. What is ‘‘quality of evidence’’ and why is it important to clinicians?BMJ, 20083; 336: 995–998.

  40. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ 2008; 336: 1049–1051.

  41. Oxlade O, Falzon D, Menzies D. The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis. Eur Respir J 2011; (In press).

  42. Guidelines for treatment of tuberculosis. 4th Edn. Geneva, WHO,2009 (WHO/HTM/TB/2009.420).

  43. Rapid Implementation of the Xpert MTB/RIF diagnostic test. Technical and operational ‘‘how-to’’ practical considerations.Geneva, WHO, 2011. Available from: whqlibdoc.who.int/publications/2011/9789241501569_eng.pdf

  44. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005–1015.

  45. Migliori GB, Lange C, Centis R, et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J 2008; 31:1155–1159.

  46. Cox H, Kebede Y, Allamuratova S, et al. Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance. PLoS Med 2006; 3: e384.

  47. Holtz TH, Lancaster J, Laserson KF, et al. Risk factors associated with default from multidrug-resistant tuberculosis treatment, South Africa, 1999–2001. Int J Tuberc Lung Dis 2006;10: 649–655.

  48. CDC, Partners In Health/NTP Peru, Partners In Health/Tomsk Prison & Civilian TB Services, NTP Latvia, NTP Estonia, TDF/NTP Philippines, WHO. Case-based data collection: First 5 DOTSPlus Projects, 2000–2004 [dataset].

  49. Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrugresistant tuberculosis. Am J Respir Crit Care Med 2010; 182:684–692.

  50. Sua´rez PG, Floyd K, Portocarrero J, et al. Feasibility and costeffectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru.Lancet 2002; 359: 1980–1989.

  51. Tupasi TE, Gupta R, Quelapio MI, et al. Feasibility and costeffectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med 2006; 3: e352.

  52. The feasibility and efficiency of controlling MDR-TB using the DOTS-Plus strategy in the Russian Federation. Geneva, WHO, 2005 (WHO/HTM/TB/2005.357C).

  53. Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and metaanalysis. PLoS One 2009; 4: e6914.

  54. Dowdy DW, O’Brien MA, Bishai D. Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis. Int J Tuberc Lung Dis 2008; 12: 1021–1029.

  55. Dowdy DW, Lourenc¸o MC, Cavalcante SC, et al. Impact and costeffectiveness of culture for diagnosis of tuberculosis in HIVinfected Brazilian adults. PLoS One 2008; 3: e4057.

  56. Menzies D, Oxlade O, Lewis M. Costs for tuberculosis care in Canada. Ottawa, Public Health Agency of Canada, 2006.

  57. The efficiency of TB laboratory services in the Russian Federation. Policy Brief Number 5. Geneva, WHO, 2005 (WHO/HTM/TB/2005.357E).

  58. Albert H. Economic analysis of the diagnosis of smear-negative pulmonary tuberculosis in South Africa: incorporation of a new rapid test, FASTPlaqueTB, into the diagnostic algorithm. Int J Tuberc Lung Dis 2004; 8: 240–247.

  59. Kamolratanakul P, Hiransithikul N, Singhadong N. Cost analysis of different types of tuberculosis patients at tuberculosis centers in Thailand. Southeast Asian J Trop Med Public Health 2002; 33: 321–330.

  60. The Economics of TB Drug Development. The Global Alliance for TB Drug Development 2001. Available from: www.tballiance.org/downloads/publications/TBA_Economics_Report.pdf

  61. Akc¸akır Y. Correlates of treatment outcomes of multidrugresistant tuberculosis (MDR-TB): a systematic review and metaanalysis. MSc Thesis. Montreal, McGill University, 2010.

  62. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640–645.

  63. Framework for implementing new tuberculosis diagnostics. Geneva, WHO, 2010. Available from: www.who.int/tb/laboratory/whopolicyframework_july10_revnov10.pdf

  64. Policy guidance on drug susceptibility testing (DST) of second-line anti-tuberculosis drugs. Geneva, WHO, 2008 (WHO/HTM/TB/2008.392). Available from: whqlibdoc.who.int/hq/2008/WHO_HTM_TB_2008.392_eng.pdf

  65. Ziganshina LE, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev 2008; 1: CD004795.

  66. Lee H, Cho SN, Bang HE, et al. Exclusive mutations related to isoniazid and ethionamide resistance among Mycobacterium tuberculosis isolates from Korea. Int J Tuberc Lung Dis 2000; 4:441–447.

  67. Burgos M, Gonzalez LC, Paz EA, et al. Treatment of multidrugresistant tuberculosis in San Francisco: an outpatient-based approach. Clin Infect Dis 2005; 40: 968–975.

  68. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010; 375:1798–1807.

  69. Eker B, Ortmann J, Migliori GB, et al. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis 2008; 14:1700–1706.

  70. El Sahly HM, Teeter LD, Pawlak RR, et al. Drug-resistant tuberculosis: a disease of target populations in Houston, Texas.J Infect 2006; 53: 5–11.

  71. Leimane V, Dravniece G, Riekstina V, et al. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000–2004. Eur Respir J 2010; 36: 584–593.

  72. Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. EurRespir J 2007; 30: 623–626.

  73. Palmero D, Ritacco V, Ambroggi M, et al. [Multidrug-resistanttuberculosis in AIDS patients at the beginning of the millennium.]Medicina (B Aires) 2006; 66: 399–404.

  74. Shean KP, Willcox PA, Siwendu SN, et al. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992–2002. Int J Tuberc Lung Dis2008; 12: 1182–1189.

  75. Varma JK, Nateniyom S, Akksilp S, et al. HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study. BMC Infect Dis 2009; 9: 42.

  76. Jamal LF, Guibu IA, Tancredi MV, et al. Reliability and usefulness of TB/HIV co-infection data proceeding from developing countries. International Conference on AIDS 2004. Available from: gateway.nlm.nih.gov/MeetingAbstracts/ma?f5102280737.

  77. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Geneva, WHO, 2010.

  78. Abdool Karim S, Naidoo K, Padayatchi N, et al. Optimal Timing of ART during TB Therapy: Findings of the SAPiT Trial. 18th Conference on Retroviruses and Opportunistic Infections, Boston, USA, 2011. Available from: www.retroconference.org/2011/Abstracts/42488.htm

  79. Havlir D, Ive P, Kendall M, et al. International randomized trial of immediate vs. early ART in HIV+ patients treated for TB: ACTG 21 STRIDE study. 18th Conference on Retroviruses and Opportunistic Infections, Boston, USA, 2011. Available from:www.retroconference.org/2011/Abstracts/41152.htm

  80. Blanc FX, Sok T, Laureillard D, et al. Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis. 18th Intl AIDS Conf, Abstract THLBB106, Vienna, Austria, 2010.Available from: www.natap.org/2010/IAS/IAS_91.htm

  81. Fitzpatrick C, Floyd K. A systematic review of the cost and costeffectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics 2011; (In press).

  82. WHO Policy on TB infection control in health-care facilities, congregate settings and households. Geneva, WHO, 2009 (WHO/HTM/TB/2009.419).

  83. Migliori GB, Loddenkemper R, Blasi F, et al. 125 years after Robert Koch’s discovery of the tubercle bacillus: the new XDR-TB threat. Is ‘‘science’’ enoughto tackle the epidemic?EurRespir J 2007; 29: 423–427.

  84. 2011 Update of the WHO Guidelines for the programmatic management of drug-resistant tuberculosis .

  85. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. http://www.who.int/publications/2011/9789241501545_eng.pdf

  86. Национальный стандарт Российской Федерации ГОСТ Р ИСО 15189-2006, Лаборатории медицинские: Частные требования к качеству и компетенции (ISO 15189:2006 Medical laboratories — Particular requirements for quality and competence), М., 2007

  87. Strategic Approach for the Strengthening of Laboratory Services for Tuberculosis Control, 2006-2009, WHO, 2006 WHO/HTM/TB/2006.364

  88. Policy Framework for Implementing New Tuberculosis Diagnostics. Policy statement World Health Organization, 2011 Pre-publication copy March 2010 http://www.who.int/tb/laboratory/whopolicy_framework_mar2011.pdf

  89. Балабанова Я.М., Дробниевский Ф. и др. Оптимизация лабораторной диагностики туберкулеза с использованием современных бактериологических и молекулярно-биологических методов// Пробл. туб. и болезн. легких – 2011- № 2- стр. 36-42

  90. M.V. Shulgina, V.N. Malakhov, S.E.Hoffner, M. Haile, A. Wright, 2009, Proficiency Assessment of M. tuberculosis Drug Susceptibility Testing in the Russian Federation, 2005-2007 Int J Tuberc Lung Dis, v. 13, #10, 1294-1300

  91. New Laboratory diagnostic tools for tuberculosis control. WHO, Stop TB Partnership, 2008

  92. 2011 Update of the WHO Guidelines for the programmatic management of drug-resistant tuberculosis (в печати).

  93. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. http://www.who.int/publications/2011/9789241501545_eng.pdf

  94. Approaches to improve sputum smear microscopy for tuberculosis diagnosis. Expert group meeting Geneva: 31 October 2009 World Health Organization Pre-publication copy http://www.who.int/tb/laboratory/egmreport_microscopymethods_nov09.pdf

  95. Fluorescent light-emitting diode (LED) microscopy for diagnosis of tuberculosis. Policy statement World Health Organization, 2011 Pre-publication copy March 2010 http://www.who.int/tb/laboratory/whopolicy_led_microscopy_mar2011.pdf

  96. Use of liquid TB culture and drug susceptibility testing in low and medium-income settings WHO, 2007. http://www.who.int/tb/laboratory/policy_statements/en/index.html

  97. Noncommercial culture and drug-susceptibility testing methods for screening patients at risk for multi-drugresistant tuberculosis Policy statement World Health Organization, 2011 Pre-publication copy March 2010 http://www.who.int/tb/laboratory/whopolicy_noncommercialcultureanddstmethods_mar2010.pdf

  98. Molecular Line-Probe Assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB) Policy statement World Health Organization, 2008 http://www.who.int/tb/publications/who_policy_line_probe_assays_revoct10_ru.pdf

  99. Andrews R.H., Radhakrishna S., A comparison of two methods of sputum collection in the diagnosis of pulmonary TB, Tubercule 1959, 40: 155 – 162

  100. Moore DA , Mendoza D , Gilman RH , et al. Incremental Benefit of One and Two Sputum Cultures as Compared with Sputum-Smear Microscopy N Engl J Med 2006; 355:1539-1550

  101. M.V. Shulgina, V.N. Malakhov, S.E.Hoffner, M. Haile, A. Wright. Proficiency Assessment of M. tuberculosis Drug Susceptibility Testing in the Russian Federation, 2005-2007// Int J Tuberc Lung Dis – 2009- v. 13, №10, pp 1294-1300

  102. Best practices in prevention, control and care for drug resistant tuberculosis World Health Organization 2013

  103. Assessing the impact of new diagnostics on tuberculosis control – 2010- Int J Tuberc Lung Dis 14(12):1506–1507 2010




Поделитесь с Вашими друзьями:
1   2   3   4   5   6   7   8   9   10   11


База данных защищена авторским правом ©zodorov.ru 2017
обратиться к администрации

    Главная страница